Loading...
•
Jun 30, 2024
Krystal Biotech Q2 2024 Earnings Report
Reported strong second quarter, driven by VYJUVEK's commercial growth and pipeline advancements.
Key Takeaways
Krystal Biotech reported a strong second quarter with $70.3 million in VYJUVEK net product revenue, a 55.3% increase compared to the first quarter of 2024. The company is progressing with its clinical pipeline and anticipates multiple clinical data readouts in the second half of 2024. They ended the quarter with $628.9 million in cash and investments.
VYJUVEK net product revenue reached $70.3 million in Q2 2024, up 55.3% from Q1 2024.
Over 400 reimbursement approvals secured for VYJUVEK in the U.S., with 97% positive access determinations.
High patient compliance with weekly VYJUVEK treatment at 90%.
Three clinical readouts are expected in the second half of 2024.
Revenue by Segment
Forward Guidance
The company anticipates approximately $150 million to $175 million of Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense for the year ending December 31, 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...